Literature DB >> 22301395

Neoadjuvant endocrine therapy: for whom, for how long?

Fatima Cardoso.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22301395     DOI： 10.1007/s12094-012-0765-7

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


× No keyword cloud information.
  10 in total

1.  Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[+] operable breast cancer.

Authors:  Antonio Llombart-Cussac; Ángel Guerrero; Antonio Galán; Vicente Carañana; Elvira Buch; Álvaro Rodríguez-Lescure; Amparo Ruiz; Carlos Fuster Diana; Vicente Guillem Porta
Journal:  Clin Transl Oncol       Date:  2012-02       Impact factor: 3.405

2.  Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.

Authors:  Mitch Dowsett; Ian E Smith; Stephen R Ebbs; J Michael Dixon; Anthony Skene; Roger A'Hern; Janine Salter; Simone Detre; Margaret Hills; Geraldine Walsh
Journal:  J Natl Cancer Inst       Date:  2007-01-17       Impact factor: 13.506

3.  Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.

Authors:  Ian E Smith; Mitch Dowsett; Stephen R Ebbs; J Michael Dixon; Anthony Skene; J-U Blohmer; Susan E Ashley; Stephen Francis; Irene Boeddinghaus; Geraldine Walsh
Journal:  J Clin Oncol       Date:  2005-07-05       Impact factor: 44.544

4.  Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.

Authors:  B Fisher; A Brown; E Mamounas; S Wieand; A Robidoux; R G Margolese; A B Cruz; E R Fisher; D L Wickerham; N Wolmark; A DeCillis; J L Hoehn; A W Lees; N V Dimitrov
Journal:  J Clin Oncol       Date:  1997-07       Impact factor: 44.544

Review 5.  Can some patients avoid adjuvant chemotherapy for early-stage breast cancer?

Authors:  Philippe L Bedard; Fatima Cardoso
Journal:  Nat Rev Clin Oncol       Date:  2011-03-01       Impact factor: 66.675

6.  Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial.

Authors:  Luigi Cataliotti; Aman U Buzdar; Shinzaburo Noguchi; Jose Bines; Yuichi Takatsuka; Katarina Petrakova; Pierre Dube; Celia Tosello de Oliveira
Journal:  Cancer       Date:  2006-05-15       Impact factor: 6.860

7.  Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy.

Authors:  Marco Colleoni; Vincenzo Bagnardi; Nicole Rotmensz; Richard D Gelber; Giuseppe Viale; Giancarlo Pruneri; Paolo Veronesi; Rosalba Torrisi; Anna Cardillo; Emilia Montagna; Elisabetta Campagnoli; Alberto Luini; Mattia Intra; Viviana Galimberti; Eloise Scarano; Giulia Peruzzotti; Aron Goldhirsch
Journal:  Breast Cancer Res Treat       Date:  2008-10-22       Impact factor: 4.872

8.  Increase in response rate by prolonged treatment with neoadjuvant letrozole.

Authors:  J Michael Dixon; Lorna Renshaw; E Jane Macaskill; Oliver Young; Juliette Murray; David Cameron; Gillian R Kerr; Dean B Evans; William R Miller
Journal:  Breast Cancer Res Treat       Date:  2008-02-09       Impact factor: 4.872

9.  Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.

Authors:  Matthew J Ellis; Yu Tao; Jingqin Luo; Roger A'Hern; Dean B Evans; Ajay S Bhatnagar; Hilary A Chaudri Ross; Alexander von Kameke; William R Miller; Ian Smith; Wolfgang Eiermann; Mitch Dowsett
Journal:  J Natl Cancer Inst       Date:  2008-09-23       Impact factor: 13.506

10.  Letrozole in the neoadjuvant setting: the P024 trial.

Authors:  Matthew J Ellis; Cynthia Ma
Journal:  Breast Cancer Res Treat       Date:  2007-10-03       Impact factor: 4.872
  10 in total
  1 in total

1.  Neoadjuvant endocrine treatment for breast cancer: from bedside to bench and back again?

Authors:  R R Saleh; N Bouganim; J Hilton; A Arnaout; M Clemons
Journal:  Curr Oncol       Date:  2014-02       Impact factor: 3.677
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.